Overview A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease Status: Terminated Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease. Phase: Phase 2 Details Lead Sponsor: Abbott